Jiesi Chen

Founded in 2015 by a distinguished team of scientists, Creative Biosciences is a leading biotechnology company focused on noninvasive early cancer detection. Our flagship product, Colosafe, is a stool DNA test for the early detection of colorectal cancer, complemented by Lunsafe, a newly NMPA-approved DNA test for lung cancer. Headquartered in Guangzhou, China, with subsidiaries in Hong Kong, the United States, and Germany, we operate state-of-the-art R&D laboratories and GMP-certified facilities covering 51,000 m²—forming a global network for research, manufacturing, and clinical collaboration. Through the acquisition of Helixgen and continuous innovation, Creative Biosciences has built strong proprietary technologies and an expanding pipeline including tests for bladder, cervical, and liver cancers, as well as POCT solutions. Guided by the mission “Human health, my mission,” we are committed to advancing next-generation diagnostic solutions that enable earlier detection, better outcomes, and broader access to cancer screening worldwide.